Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F I Navetta

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Southern Medical Journal|July 1, 1987
Acute myocardial infarction associated with initial cocaine useC S Wehbie, H J Vidaillet, F I Navetta, et al.
Biophysical Journal|March 1, 1986
Single-channel studies on linear gramicidins with altered amino acid side chains. Effects of altering the polarity of the side chain at position 1 in gramicidin AE W Russell, L B Weiss, F I Navetta, et al.
Coronary Artery Disease|February 1, 1993
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplastyS G Ellis, J E Tcheng, F I Navetta, et al.
Journal of the American College of Cardiology|October 1, 1994
Predicting the risk of abrupt vessel closure after angioplasty in an individual patientA N Tenaglia, D F Fortin, R M Califf, et al.
Circulation|April 15, 1995
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT InvestigatorsJ E Tcheng, R A Harrington, K Kottke-Marchant, et al.
Catheterization and Cardiovascular Diagnosis|April 1, 1996
Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplastyP A Gurbel, F I Navetta, E R Bates, et al.
Circulation|February 18, 1997
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI InvestigatorsE M Ohman, N S Kleiman, G Gacioch, et al.
Circulation|May 31, 2001
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter studyS R Steinhubl, J D Talley, G A Braden, et al.
Circulation|November 1, 1996
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trialS P Schulman, P J Goldschmidt-Clermont, E J Topol, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Southern Medical Journal|July 1, 1987
Acute myocardial infarction associated with initial cocaine useC S Wehbie, H J Vidaillet, F I Navetta, et al.
Biophysical Journal|March 1, 1986
Single-channel studies on linear gramicidins with altered amino acid side chains. Effects of altering the polarity of the side chain at position 1 in gramicidin AE W Russell, L B Weiss, F I Navetta, et al.
Coronary Artery Disease|February 1, 1993
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplastyS G Ellis, J E Tcheng, F I Navetta, et al.
Journal of the American College of Cardiology|October 1, 1994
Predicting the risk of abrupt vessel closure after angioplasty in an individual patientA N Tenaglia, D F Fortin, R M Califf, et al.
Circulation|April 15, 1995
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT InvestigatorsJ E Tcheng, R A Harrington, K Kottke-Marchant, et al.
Catheterization and Cardiovascular Diagnosis|April 1, 1996
Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplastyP A Gurbel, F I Navetta, E R Bates, et al.
Circulation|February 18, 1997
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI InvestigatorsE M Ohman, N S Kleiman, G Gacioch, et al.
Circulation|May 31, 2001
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter studyS R Steinhubl, J D Talley, G A Braden, et al.
Circulation|November 1, 1996
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trialS P Schulman, P J Goldschmidt-Clermont, E J Topol, et al.
Pageof 1